Abstract: 【Abstract】 Objective To evaluate clinical efficacy and safety of omalizumab in the treatment of symptomatic dermographism by analyzing real-world data. Methods Clinical data were collected from patients with symptomatic dermographism who completed 16-week treatment with omalizumab in Department of Dermatology, Peking University First Hospital from February 2018 to May 2021, and retrospectively analyzed. The analysis was done by comparing data obtained before and after the treatment, including critical friction thresholds（CFTs）, pruritus scores in a provocation test, as well as urticaria control test （UCT）, dermatology life quality index （DLQI） and chronic urticaria quality of life questionnaire（CU-Q2oL）scores. Adverse events reported by patients during the treatment were recorded. Wilcoxon signed-rank test was applied for the analysis of clinical data before and after the treatment. Results A total of 27 patients with symptomatic dermographism who completed 16 weeks of omalizumab treatment were included. At baseline, the CFTs of all the 27 patients were 4, and their UCT, DLQI and CU-Q2oL scores were 7.0 （5.0, 8.0）, 9.0 （6.0, 10.0）, 63.0 （50.0, 72.0） points respectively. At week 4, the CFTs decreased from 4 to 0 in 9 patients （33.3%）, the UCT scores increased to 14.0 （12.0, 16.0） points （Z = 4.548, P＜0.05）, and the DLQI and CU-Q2oL scores decreased to 2.0 （0.0, 2.0） and 32.0 （25.0, 41.0） points respectively in the 27 patients （Z = 4.513, 4.433, respectively, both P＜0.05）. At week 6, the UCT scores increased to 15.0 （14.0, 16.0） points, and the DLQI and CU-Q2oL scores decreased to 0.0 （0.0, 1.0） and 25.0 （23.0, 30.0） points respectively in the 27 patients. No drug-related serious adverse events were reported during the treatment. Conclusion Omalizumab can effectively improve the symptoms of symptomatic dermographism and patients′ quality of life with a good safety profile.

Key words: Urticiaria, Treatment outcome, Dermographism, Omalizumab